Cutaneous Leishmaniasis Diagnostic Study

Sponsor
Institute of Tropical Medicine, Belgium (Other)
Overall Status
Recruiting
CT.gov ID
NCT03837431
Collaborator
(none)
350
1
46.6
7.5

Study Details

Study Description

Brief Summary

The performance of the CL Detect Rapid test will be tested in individuals with suspected cutaneous leishmaniasis in Ethiopia using both skin slit and dental broach samples against a combined reference of microscopy and PCR. Alternative sampling methods will also be evaluated.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Skin slit
  • Diagnostic Test: Dental broach
  • Diagnostic Test: Tape disc

Detailed Description

Cutaneous Leishmaniasis is common in Ethiopia and mainly affects the poor living in rural areas. Diagnosis of CL routinely uses invasive skin slits which are examined with microscopy, requiring trained staff and an equipped lab. A new rapid diagnostic test for CL which may be used in the field has been developed and validated in several countries where other Leishmania species are present. Less invasive tape sampling has also become available. Whether this new RDT and alternative sampling methods can be used in Ethiopia is unclear.

The performance of the CL detect Rapid Test against a combined reference (microscopy and PCR) and alternative sample collection methods will be tested in CL suspected individuals in North-West Ethiopia in a cross-sectional study.

Study Design

Study Type:
Observational
Anticipated Enrollment :
350 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Diagnosis of Cutaneous Leishmaniasis Using the CL-Detect Rapid Test in Ethiopia
Actual Study Start Date :
Feb 13, 2019
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 31, 2022

Arms and Interventions

Arm Intervention/Treatment
CL suspicion

Individuals presenting with clinical suspicion of CL

Diagnostic Test: Skin slit
Skin slit microscopy, RDT and PCR

Diagnostic Test: Dental broach
Dental broach RDT and PCR

Diagnostic Test: Tape disc
Tape disc PCR

Outcome Measures

Primary Outcome Measures

  1. Sensitivity, specificity of CL detect Rapid Test using skin slit sampling [February 2019]

    % test positive/negative compared against a combined reference of microscopy and PCR with skin slit sampling(positive if any of the two are positive)

Secondary Outcome Measures

  1. Sensitivity, specificity of CL detect Rapid Test using dental broach sampling [February 2019]

    CL detect Rapid Test against combined reference of microscopy and PCR using skin slit sampling

  2. Sensitivity, specificity of CL detect Rapid Test with skin slit or dental broach sampling [May 2018]

    CL detect Rapid Test with skin slit sample against CL detect Rapid Test with dental broach sample

  3. Sensitivity, specificity of CL detect Rapid Test compared to routine [February 2019]

    CL detect Rapid Test positive/negative with skin slit sample compared to microscopy with skin slit sample

  4. Sensitivity, specificity of dental broach sample compared to skin slit sample [February 2019]

    PCR with dental broach compared to PCR with skin slit sample

  5. Sensitivity, specificity of tape disc sampling [February 2019]

    PCR with tape disc sampling compared to PCR with skin slit sampling

  6. Sensitivity, specificity of routine testing [February 2019]

    Microscopy with skin slit sampling compared to PCR with skin slit sampling

  7. Species identification [February 2019]

    For selected CL lesions species identification will be done

  8. Immunomodulatory mediators in CL lesions using non-invasive sampling [February 2019]

    Tape disc samples will be used and correlation with lesion severity will be assessed

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical suspicion of CL
Exclusion Criteria:
  • ≤ 2 years of age

  • Not willing or able to provide consent/assent

  • CL presentation with only lesions for which skin slit samples cannot be obtained (e.g. eyelids)

  • Co-morbidity with visceral leishmaniasis

  • On CL treatment at time of enrollment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Leishmania Research and Treatment Center, University of Gondar hospital Gondar Ethiopia

Sponsors and Collaborators

  • Institute of Tropical Medicine, Belgium

Investigators

  • Study Chair: Johan van Griensven, MD, PhD, Institute of Tropical Medicine, Antwerp, Belgium
  • Principal Investigator: Rezika Mohammed, MD, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Institute of Tropical Medicine, Belgium
ClinicalTrials.gov Identifier:
NCT03837431
Other Study ID Numbers:
  • 1219/18
First Posted:
Feb 12, 2019
Last Update Posted:
Mar 8, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Institute of Tropical Medicine, Belgium
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 8, 2022